Britain’s Tolemy Bio has closed a €1.4 million pre-seed round led by Norrsken Evolve.
The company focuses on helping cell and gene therapy developers make better use of the large amounts of experimental data they produce.
Peek inside the pitch deck ...
Want to read this article? Subscribe to TFN Prime at super early discounted price